ArticleCase reports in ophthalmological medicine2026
Central Serous Chorioretinopathy Deteriorated With Everolimus Administration in Advanced Renal Cell Carcinoma: A Case Report.
Article in Case reports in ophthalmological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Everolimus, an antineoplastic drug, is associated with various systemic adverse effects. This case report is aimed at presenting a novel ophthalmological complication, drug-associated central serous chorioretinopathy (CSCR), following everolimus administration. Methods: A 54-year-old male with metastatic renal cell carcinoma presented with blurred vision and metamorphopsia. Comprehensive ophthalmologic examination, including multimodal imaging with optical coherence tomography (OCT), fluorescein angiography (FA), and fundus autofluorescence (FAF), was performed. A thorough review of his medical history and recent medication changes was conducted to identify potential associating factors. Results: Multimodal imaging confirmed bilateral CSCR with subretinal fluid and pachychoroid features. The only recent change in his medication regimen was the initiation of everolimus (10 mg daily) 1 month prior to symptom onset. All other known risk factors for CSCR, such as corticosteroid use, were absent. Upon discontinuation of everolimus, the patient's symptoms and visual acuity improved. Follow-up OCT imaging demonstrated complete resolution of the subretinal fluid. Conclusion: Everolimus can potentially be a risk factor for subclinical CSCR deterioration in prone population. Ophthalmologists and oncologists should be aware of this rare but significant adverse effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.